NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024 (2024)

Delayed Nasdaq Other stock markets 01:00:48 2024-08-15 pm EDT			5-day change	1st Jan Change
2.630 ^USD	-7.72%		-2.95%	+23.47%

Aug. 14	Transcript : NEXGEL, Inc., Q2 2024 Earnings Call, Aug 14, 2024
Aug. 14	Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.4M, vs. Street Est of $1.4M	MT

Summary

Quotes

Charts

News

Company

Financials

Valuation

Consensus

Calendar

Latest news about NEXGEL, Inc.

Transcript : NEXGEL, Inc., Q2 2024 Earnings Call, Aug 14, 2024	Aug. 14
Earnings Flash (NXGL) NEXGEL Reports Q2 Revenue $1.4M, vs. Street Est of $1.4M	Aug. 14	MT
NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024	Aug. 14	CI
Nexgel Launching $1.1 Million Direct Offering	Aug. 12	MT
NEXGEL, Inc. and Innovative Optics US Initiate Institutional Review Board Study in Accordance with FDA of Hydrogel Application During Laser Hair Removal	Jul. 18	CI
NEXGEL, Inc. Provides Preliminary Revenue Guidance for the Second, Third and Fourth Quarter of 2024	Jul. 08	CI
NEXGEL Secures Distribution Deal for SilverSeal Wound Dressing With Cintas	Jun. 27	MT
Nexgel, Inc. to Supply Silverseal to Cintas Corporation	Jun. 27	CI
Nexgel and Stada Partner to Launch Leading European Dao Enzyme Supplement, Histasolv, in North America	Jun. 11	CI
NEXGEL, Inc. acquired Silly George.	May. 15	CI
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.	May. 13	CI
NEXGEL, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Transcript : NEXGEL, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (NXGL) NEXGEL Reports Q1 Revenue $1.3M, vs. Street Est of $1.2M	May. 13	MT
Tranche Update on NEXGEL, Inc.'s Equity Buyback Plan announced on December 7, 2022.	Apr. 10	CI
NEXGEL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Transcript : NEXGEL, Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Earnings Flash (NXGL) NEXGEL Posts Q4 Revenue $1.1M	Apr. 01	MT
NEXGEL, Inc. Provides Revenue Guidance for the First Quarter of 2023	Apr. 01	CI
NEXGEL, Inc. Announces Intention of Miranda J. Toledano to Resign as a Member of the Board of Directors, Effective as of March 31, 2024	Jan. 16	CI
Top Premarket Decliners	Jan. 16	MT
Nexgel Subsidiary, Cg Converting and Packaging, Begins 12,000 Square Foot Expansion of Texas Facility to Support the Expected Growth in Product Demand in 2024	Jan. 09	CI
NEXGEL, Inc. Announces Resignation of David Stefansky as Member of the Board of Directors	Dec. 12	CI
Nexgel Enters Deal With Stada Arzneimittel to Distribute OTC Products Across North America	Dec. 11	MT
NEXGEL, Inc. Announces Partnership with STADA Arzneimittel AG to Distribute and Commercialize Consumer Health OTC Products in North America	Dec. 11	CI

Chart NEXGEL, Inc.

Duration

Period

More charts

Company Profile

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including ultra-gentle, high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CG labs segment comprises the CG Converting and Packaging, LLC used for the Companyâs converting and packaging business, which is based in Granbury, Texas. Its hydrogel consumer products are marketed under the brand names MedaGel and LumaGel Beauty. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. It also specializes in eye and eyelash consumer products.

Employees

Sector

Pharmaceuticals

Calendar

2024-11-04 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.850USD

Average target price

6.000USD

Spread / Average Target

+110.53%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Stock Market
Equities
NXGL Stock
News NEXGEL, Inc.
NEXGEL, Inc. Reiterates Revenue Guidance for the Third Quarter and Fourth Quarter of 2024

Protect and grow your investments with the help of our experts Secure my Investments

"); for (var element in ICConf) { if (document.getElementById("zpp"+element)) { document.getElementById("zpp"+element).innerHTML = ""; } } InvestingChannelQueue.push(function() { ic_page = InvestingChannel.UAT.Run("5c5a75c3-8896-4592-98f8-dc06e6fdcc56"); }); } gaEvent('adspv', 'InvestingChannel_v2', 'US');googletag.cmd.push(function() { googletag.pubads().setTargeting('Edition', 'en_US');googletag.pubads().setTargeting('UserType', 'free');googletag.pubads().setTargeting('Content', 'equities');googletag.pubads().setTargeting('codezb', '130833484');googletag.enableServices();googletag.pubads().collapseEmptyDivs();try{googletag.pubads().getSlots().forEach(function(slot){if(slot.getSlotElementId().startsWith('zpp')){;}else{googletag.pubads().refresh([slot],{changeCorrelator: false});}})}catch(error){console.error(error)}});$(document).ready(function() { $( document).on('zbv_visible',function () {startAdsService();}); if (document[zbv_hidden]===false) { startAdsService(); } });